Anbio Biotechnology and Oncocyte Compared in Head-to-Head Analysis

Analysts see more upside potential in Oncocyte, but Anbio has higher revenue and earnings

Feb. 22, 2026 at 10:04pm

Got story updates? Submit your updates here. ›

Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX) are both manufacturing companies, but a head-to-head analysis shows Anbio has the edge on several key metrics including revenue, earnings, and profitability. However, analysts believe Oncocyte has more upside potential based on its consensus price target.

Why it matters

The comparison between these two biotech companies provides insight into their relative strengths and weaknesses, which could be valuable for investors evaluating potential investments in the diagnostics and medical technology space.

The details

The analysis found that Anbio Biotechnology has higher revenue and earnings than Oncocyte. Anbio also beats Oncocyte on 6 out of 10 factors compared, including net margins, return on equity, and return on assets. However, analysts have a consensus price target of $12 for Oncocyte, suggesting a potential upside of over 118%, compared to less bullish forecasts for Anbio.

  • The analysis is based on the most recent financial data available as of February 22, 2026.

The players

Anbio Biotechnology

A medical technology company dedicated to advancing in vitro diagnostics (IVD) products, with a focus on transforming the diagnostics landscape through personalized and decentralized solutions.

Oncocyte

A molecular diagnostics company that researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the nuanced differences between these two biotech companies, with Anbio Biotechnology demonstrating stronger financial performance but Oncocyte potentially offering more upside potential according to analyst projections. Investors evaluating the diagnostics and medical technology sector may want to closely examine the specific strengths and weaknesses of each company to determine the best fit for their investment goals.